Etanercept provides a more physiological approach in the treatment of psoriasis

Dermatologic Therapy

Volumn 21, Issue SUPPL. 2, 2008, Pages

  Altomare, Gianfranco ^a   Ayala, Fabio ^b   Berardesca, Enzo ^c   Chimenti, Sergio ^d   Giannetti, Alberto ^e   Girolomoni, Giampiero ^f   Lotti, Torello ^g   Martini, Patrizia ^h   Peserico, Andrea ⁱ   Guerra, Antonio Puglisi ^j   Vena, Gino A ^k  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f UNIVERSITY OF VERONA   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h Lucca Hospital   (Italy)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j Messina Hospital   (Italy)

^k UNIVERSITY OF BARI   (Italy)

more..

Author keywords

Adalimumab; Efalizumab; Etanercept; Infliximab; Psoriasis; TNF

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; GAMMA INTERFERON; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12 RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE; PLACEBO; RETINOID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; VITAMIN D DERIVATIVE;

ASPERGILLOSIS; BONE MARROW DEPRESSION; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GRANULOMATOUS INFLAMMATION; HISTOPLASMOSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LISTERIOSIS; LIVER TOXICITY; LOW DRUG DOSE; NEPHROTOXICITY; NOCARDIOSIS; NONHUMAN; PNEUMONIA; PSORIASIS; PUVA; QUALITY OF LIFE; REBOUND; REVIEW; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TERATOGENICITY; TUBERCULOSIS;

ANIMALS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 53149101296     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2008.00226.x     Document Type: Review

References (93)

1. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005 : 352 : 1899 1912.
2. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996 : 14 : 485 496.
3. Alenius GM, Stenberg B, Stenlund H, Lundblad M, Dahlqvist SR. Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol 2002 : 29 : 2577 2582.
4. Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002 : 82 : 108 113.
5. Gisondi P, Girolomoni G, Sampogna F, Tabolli S, Abeni D. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 2005 : 15 : 279 283.
6. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003 : 111 : 821 831.
7. Gisondi P, Tinazzi I, El-Dalati G, et al. Lower limbs enthesopathy in psoriatic patients without clinical signs of arthropathy: a hospital based case-control study. Ann Rheum Dis 2008 : 67 : 26 30.
8. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr., Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 : 41 : 401 407.
9. Choi J, Koo JK. Quality of life issues in psoriasis. J Am Acad Dermatol 2003 : 49 (2 Suppl S57 S61.
10. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007 : 445 : 866 873.
11. Guttman-Yassky E, Krueger JG. Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol 2007 : 157 : 1103 1115.
12. Sabat R, Philipp S, Höflich C, et al. Immunopathogenesis of psoriasis. Exp Dermatol 2007 : 16 : 779 798.
13. Ottaviani C, Nasorri F, Bedini C, et al. CD56 bright CD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 2006 : 36 : 118 128.
14. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes. Synergistic or antagonist effects with interferon-gamma; and tumor necrosis factor-alpha. J Immunol 1999 : 162 : 494 502.
15. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006 : 36 : 1309 1323.
16. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006 : 203 : 2577 2587.
17. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007 : 445 : 648 651.
18. Baker BS, Powles AV, Valdimarsson H, Fry L. An altered response by psoriatic keratinocytes to gamma interferon. Scand J Immunol 1988 : 28 : 735 740.
19. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007 : 449 : 564 569.
20. Mussi A, Bonifati C, Carducci M, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997 : 11 : 115 118.
21. Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 2004 : 279 : 32633 32642.
22. Kawaguchi M, Mitsuhashi Y, Kondo S. Overexpression of tumour necrosis factor-alpha-converting enzyme in psoriasis. Br J Dermatol 2005 : 152 : 915 919.
23. Victor FC, Gottlieb AB. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol 2002 : 1 : 264 275.
24. Tan JK, Aphale A, Malavita R, Sun Y, Gottlieb AB. Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc 2007 : 12 : 38 45.
25. Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004 : 63 : 769 773.
26. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004 : 6 : R326 R334.
27. + T lymphocytes and impairs dendritic cell functions. Br J Dermatol 2007 : 157 : 249 258.
28. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005 : 175 : 2721 2729.
29. Papp KA, Caro I, Leung HM, Mease PJ. Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 2007 : 11 : 57 66.
30. Dubertret L, Sterry W, Bos JD, et al. CLEAR Multinational Study Group. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006 : 155 : 170 181.
31. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002 : 301 : 418 426.
32. Furst DE, Wallis R, Broder M, Beenhouwe DO. Tumor Necrosis Factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006 : 36 : 159 167.
33. Kohno T, Tam L-TT, Stevens SR, Louie JS. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J Investig Dermatol Symp Proc 2007 : 12 : 5 8.
34. Haider AS, Cardinale IR, Whynot JA, Krueger JG. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Invest Dermatol Symp Proc 2007 : 12 : 9 15.
35. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007 : 204 : 3183 3194.
36. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005 : 41 (Suppl. 3 S199 S203.
37. Wallis RS. Reactivation of latent tuberculosis by TNF blockade: the role of interferon-gamma. J Investig Dermatol Symp Proc 2007 : 12 : 16 21.
38. Malaviya R, Sun Y, Tan JK, et al. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol 2006 : 55 : 590 597.
39. Vena GA, Cassano N. Anti-tumor necrosis factor therapies for psoriasis. Expert Rev Dermatol 2007 : 2 : 335 349.
40. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB Jr. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003 : 9 : 2.
41. Morison WL, Baughman RD, Day RM. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998 : 134 : 595 598.
42. Langan SM, Heerey A, Barry M, Barnes L. Cost analysis of narrowband UVB phototherapy in psoriasis. J Am Acad Dermatol 2004 : 50 : 623 626.
43. Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm 2004 : 10 : 318 325.
44. Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontination of psoralen-ultraviolet A: a cohort study. J Invest Dermatol 2003 : 121 : 252 258.
45. Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006 : 298 : 7 15.
46. Shear NH. Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability? Drug Saf 2006 : 29 : 49 66.
47. Sanchez Carazo JL, Mahiques Santos L, Oliver Martinez V. Safety of etanercept in psoriasis: a critical review. Drug Saf 2006 : 29 : 675 685.
48. Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006 : 33 : 1442 1446.
49. Leon A, Nguyen A, Letsinger J, Koo J. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options. Expert Opin Pharmacother 2007 : 8 : 617 632.
50. Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatolog Treat 2006 : 17 : 29 37.
51. Opmeer BC, Heydendael VM, De Borgie CA, et al. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol 2004 : 140 : 685 690.
52. Saurat JH, Stingl G, Dubertret L, et al for the CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2007 Nov 28.
53. Haustein U-F, Rytte M. Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol 2000 : 14 : 382 388.
54. Zachariae C, Mørk NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the efficacy in active plaque psoriasis in patients with an inadequate response to methotrexate therapy: a pilot study. 21st World Congress Dermatology, Buenos Aires, 2007; Abstract ID 435.
55. van de Kerkhof PC. Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments. J Eur Acad Dermatol Venereol 2006 : 20 : 639 650.
56. Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 2006 : 54 (3 Suppl. 2 S101 S111.
57. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006 : 10 : 1 233.
58. van de Kerkhof P, Paolozzi L, Wajdula J. Etanercept 50 mg once weekly is effective and well tolerated in patients with moderate-to-severe plaque psoriasis. 66th Annual Meeting of the American Academy of Dermatology, San Antonio, 2008; Abstract ID 9477.
59. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003 : 25 : 2487 2505.
60. Gordon KB, Gottlieb AB, Leonardi CL, et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatol Treat 2006 : 17 : 9 17.
61. Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006 : 54 (4 Suppl. 1 S171 S181.
62. Vermeire S, Noman M, Van Assche G, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003 : 348 : 601 608.
63. Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006 : 33 : 31 36.
64. de Vries MK, Wolbink GJ, Stapel SO, et al. Decreased clinical response to infliximab in ankylosing spondylitis (AS) is correlated with anti-infliximab formation. Ann Rheum Dis 2007 : 66 : 1252 1254.
65. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007 : 66 : 921 926.
66. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007 : 143 : 719 726.
67. Cassano N, Loconsole F, Galluccio A, Miracapillo A, Pezza M, Vena GA. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (POWER study). Int J Immunopathol Pharmacol 2006 : 19 : 225 229.
68. Paller AS, Siegfried EC, Langley RG, et al Etanercept Pediatric Psoriasis Study Group. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008 : 358 : 241 251.
69. Papoutsaki M, Costanzo A, Mazzetta A, Gramiccia A, Soda R, Chimenti S. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol 2006 : 154 : 181 183.
70. Mease P. Psoriatic arthritis update. Bull NYU Hosp Jt Dis 2006 : 64 : 25 31.
71. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007 : 56 : 598 603.
72. Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005 : 153 : 1192 1199.
73. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006 : 367 : 6 7.
74. Krishnan R, Cella D, Leonardi C, et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007 : 157 : 1275 1277.
75. Bongartz T, Sutton AAJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 : 295 : 2275 2285.
76. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004 : 50 : 372 379.
77. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004 : 38 : 1261 1265.
78. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD the Biobadaser Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003 : 48 : 2122 2127.
79. Ehlers S. Role of tumor necrosis factor (TNF) host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis 2003 : 62 (Suppl. II ii37 ii42.
80. Plessner HL, Lin PL, Kohno T, et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007 : 195 : 1643 1650.
81. Cabou C, Bagheri H, Cantagrel A, Mazieres B, Montastruc JL. Retrospective analysis of adverse effects of infliximab in a hospital rheumatology service. Therapie 2003 : 58 : 457 462.
82. Dixon WG, Watson K, Lunt M, et al for The British Society for Rheumatology Biologics Register. Rates of serious infections, including site-specific and bacterial intracellular infections, in rheumatoid arthritis patients receiving anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006 : 54 : 2368 2376.
83. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: association with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006 : 54 : 628 634.
84. ®) therapy. Arthritis Rheum 2001 : 44 (Suppl S77 (Abstract 150).
85. Pearce DJ, Feldman SR. Update on infliximab: an intravenous biologic therapy for psoriasis. Expert Rev Dermatol 2007 : 2 : 707 713.
86. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006 : 20 : 757 790.
87. Conway PA, Reeves P, Lloyd A, Baxter G. Cost effectiveness in patients with plaque psoriasis meeting BAD criteria for biological interventions. Br J Dermatol 2006 : 155 (Suppl. 1 33 34.
88. Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006 : 10 : 1 239.
89. National Institute for Health Clinical Excellence. Etanercept and infliximab for the treatment of adults with psoriatic arthritis. London (UK): National Institute for Health and Clinical Excellence (NICE); July 2006, 33 pp. (Technology Appraisal Guidance; no. 104).
90. Bravo Vergel Y, Hawkins NS, Claxton K, et al. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology (Oxford) 2007 : 46 : 1729 1735.
91. Bansback NJ, Ara R, Barkham N, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) 2006 : 45 : 1029 1038.
92. Fleischmann R, Iqbal I. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging 2007 : 24 : 239 254.
93. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 : 153 : 486 497.